These multifaceted properties explain why nitro-nannocystin demonstrates superior potency compared to the traditional single-target inhibitor MK-2206 (which showed higher IC50 values in CRC cells despite targeting AKT1), and accounts for its context-dependent efficacy across various cancer cell lines [43]. This evidence concerns the gene AKT1 and cancer.